WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Whitehawk Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.01+0.12 (+4.15%)
Close on Oct 19, 2026
- Market cap
- $249.49M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
89.4%
Operating margin
-1601.1%−1582.9 pts over 5 years
Net margin
-288.3%−263.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -72.5% | -22.3% | -12.6% | – | |
| Gross profit | -72.2% | -22.8% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 22.2% | 32.3% | -21.8% | |
| Return on assets | -1406.3% | -11.8% | -18.6% | |
| Current ratio | 0.15 | 0.62 | 10.26 | |
| Interest coverage | -1673.1× | -3.1× | – | |
| Inventory turnover | – | – | 0.3× | |
| Capex to revenue | – | 0.1% | 7.7% | |
| Diluted shares | 0M | 3M | 62M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Whitehawk Therapeutics generated $288.71M from operations and spent $11.08M on capital expenditure, dividends and share buybacks. 60% of that went back into the business.
Generated
$288.71M
Used
$11.08M
Capital expenditure$6.67M60%Dividends$4.41M40%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-288.3%
×Asset turnover0.06×
×Equity multiplier1.17×
=Return on equity, FY2025-21.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -288.3% | 0.06× | 1.17× | -21.8% |
| FY2024 | -245.1% | 0.26× | 1.29× | -80.8% |
| FY2023 | -270.0% | 0.15× | 1.20× | -49.9% |
| FY2022 | -397.7% | 0.09× | 1.16× | -41.1% |
| FY2021 | -786.4% | 0.16× | 1.43× | -177.6% |
| FY2020 | -24.8% | 0.48× | -2.73× | 32.3% |
| FY2018 | -51.6% | 0.47× | 1.12× | -27.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$20.60M
- Cash generatingOperating cash flow above zero-$97.43M
- Return on assets improvedROA up on the prior year-48.1% → -29.3%
- Earnings backed by cashOperating cash flow above net income-$97.43M vs -$20.60M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.59 → 10.26
- No dilutionShare count did not rise27M → 62M
- Gross margin improvedGross margin up on the prior year88.36% → 89.36%
- More efficientAsset turnover rose0.20 → 0.10